<SEC-DOCUMENT>0001104659-21-016781.txt : 20210209
<SEC-HEADER>0001104659-21-016781.hdr.sgml : 20210209
<ACCEPTANCE-DATETIME>20210209172207
ACCESSION NUMBER:		0001104659-21-016781
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210207
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210209
DATE AS OF CHANGE:		20210209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ocugen, Inc.
		CENTRAL INDEX KEY:			0001372299
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36751
		FILM NUMBER:		21607923

	BUSINESS ADDRESS:	
		STREET 1:		5 GREAT VALLEY PARKWAY
		STREET 2:		SUITE 160
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		484-328-4698

	MAIL ADDRESS:	
		STREET 1:		5 GREAT VALLEY PARKWAY
		STREET 2:		SUITE 160
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HISTOGENICS CORP
		DATE OF NAME CHANGE:	20060810
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm215707d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ocgn="http://deitaxonomy.com/20210207">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_ocgn_deitaxonomy.com_20210207 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20210207_20210207 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001372299 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:EntityCentralIndexKey">0001372299</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2021-02-07to2021-02-07" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="ocgn-20210207.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2021-02-07to2021-02-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001372299</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-07</xbrli:startDate>
        <xbrli:endDate>2021-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_903_edei--DocumentType_c20210207__20210207_zU5bSIa4QbX1"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 OR 15
(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event
Reported): <b><span id="xdx_901_edei--DocumentPeriodEndDate_c20210207__20210207_zhIROas01J0c"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February  7,
2021</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityRegistrantName_c20210207__20210207_zTXKqP92tc65"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:EntityRegistrantName">OCUGEN, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20210207__20210207_zaxzARTcHzB6"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityFileNumber_c20210207__20210207_zCuqmIE3RXOl"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:EntityFileNumber">001-36751</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20210207__20210207_zv7dlxNvdV5j"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:EntityTaxIdentificationNumber">04-3522315</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">(State or Other Jurisdiction of</span></p>
                                                        <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Incorporation)</span></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Commission</span></p>
                                                        <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">File Number)</span></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer</span></p>
                                                        <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Identification Number)</span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20210207__20210207_z9xxZy2G2cCa"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:EntityAddressAddressLine1">263 Great Valley Parkway</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityAddressCityOrTown_c20210207__20210207_zTlproBwgyPc"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:EntityAddressCityOrTown">Malvern</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20210207__20210207_zp5I9mCQSVw7"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Pennsylvania</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20210207__20210207_z3i3Fg5e3vA5"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:EntityAddressPostalZipCode">19355</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_902_edei--CityAreaCode_c20210207__20210207_zL7SJPmK2dka"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:CityAreaCode">484</ix:nonNumeric></span>) <span id="xdx_901_edei--LocalPhoneNumber_c20210207__20210207_zUJfVDNSSbel"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:LocalPhoneNumber">328-4701</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Addresses, including zip code, and telephone
numbers, including area code, of principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8&#8211;K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.35in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_904_edei--WrittenCommunications_c20210207__20210207_z4DvxyIz2cFj"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.35in; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_906_edei--SolicitingMaterial_c20210207__20210207_zPCj658GBs8g"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule&#160;14a&#8211;12 under the Exchange Act (17 CFR 240.14a&#8211;12)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.35in; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementTenderOffer_c20210207__20210207_zJFlBc9N6Tm5"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre&#8211;commencement
communications pursuant to Rule&#160;14d&#8211;2(b)&#160;under the Exchange Act (17 CFR 240.14d&#8211;2(b))</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.35in; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20210207__20210207_zrwfWVNahUmb"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre&#8211;commencement
communications pursuant to Rule&#160;13e&#8211;4(c)&#160;under the Exchange Act (17 CFR 240.13e&#8211;4(c))</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Securities registered pursuant to Section
12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 39%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title of each class</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 39%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name of each exchange on which registered</b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--Security12bTitle_c20210207__20210207_z5nsT19GEDzd"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:Security12bTitle">Common Stock, $0.01 par value per share</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--TradingSymbol_c20210207__20210207_zJE19qe8dvll"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" name="dei:TradingSymbol">OCGN</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90F_edei--SecurityExchangeName_c20210207__20210207_z5NE3qVeCJsc"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(The Nasdaq Capital Market)</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of
the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company <span style="font-family: Wingdings"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20210207__20210207_zZpsxuDLwJw4"><ix:nonNumeric contextRef="From2021-02-07to2021-02-07" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange
Act. <span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
1.01 Entry into a </b></span><b>Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February&#160;7, 2021, Ocugen,&#160;Inc.
(the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) entered into a Securities Purchase Agreement (the &#8220;<span style="text-decoration: underline">Purchase Agreement</span>&#8221;)
with certain purchasers named therein (the &#8220;<span style="text-decoration: underline">Purchasers</span>&#8221;), pursuant to which the Company agreed to issue and sell,
in a registered direct offering (the &#8220;<span style="text-decoration: underline">Offering</span>&#8221;), 3,000,000 shares (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;) of the
Company&#8217;s common stock, par value $0.01 per share (the &#8220;<span style="text-decoration: underline">Common Stock</span>&#8221;), at an offering price of $7.65 per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement contains customary
representations and warranties and agreements of the Company and the Purchasers and customary indemnification rights and obligations
of the parties. The closing of the Offering is expected to occur on February&#160;10, 2021, subject to customary closing conditions.
The Company is expected to receive gross proceeds of approximately $23.0 million in connection with the Offering, before deducting
placement agent fees and related offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As
compensation to H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;<span style="text-decoration: underline">Placement Agent</span>&#8221;) as placement agent in connection
with the Offering, the Company agreed to pay to the Placement Agent a cash fee of 7.0% of the aggregate gross proceeds raised in
the Offering, plus reimbursement of certain expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summary of the Purchase Agreement
does not purport to be complete and is subject to, and qualified in its entirety by, the form of such document attached as Exhibit&#160;10.1
to this Current Report on Form&#160;8-K (the &#8220;<span style="text-decoration: underline">Report</span>&#8221;), which is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Shares in the Offering were offered
by the Company pursuant to a registration statement on Form&#160;S-3 (File No.&#160;333-237456), which was filed with the Securities
and Exchange Commission (the &#8220;<span style="text-decoration: underline">Commission</span>&#8221;) on March&#160;27, 2020, and was declared effective by the Commission
on May&#160;5, 2020. <span style="background-color: white">A copy of the opinion of </span>Troutman Pepper Hamilton Sanders LLP
<span style="background-color: white">relating to the legality of the issuance and sale of the Shares in the Offering is attached
as Exhibit&#160;5.1 hereto. This Report shall not constitute an offer to sell or the solicitation of an offer to buy the Shares,
nor shall there be any sale of the Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Updated Risk Factors</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Offering, the Company has also supplemented
its risk factor disclosure contained in the Company&#146;s prior filings with the Commission, including those discussed in the
Company&#146;s most recent Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2019, filed with the
Commission on March 27, 2020, as supplemented by the Company&#146;s subsequent filings with the Commission. The additional risk
factors are set forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risk Related to Our Development of COVAXIN</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>COVAXIN, the COVID-19 vaccine candidate that is the subject
of our co-development and license agreement with Bharat Biotech, is being evaluated by Bharat Biotech in Phase 3 clinical trials
in India and the regulatory path in the United States is currently being evaluated. We may be unable to successfully produce and
commercialize a vaccine that effectively and safely treats the virus in a timely manner, if at all, and ultimately may be unable
to obtain emergency use authorization or regulatory approval in the United States.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2021, we entered into a co-development and license
agreement, or the COVAXIN Agreement, with Bharat Biotech International Ltd., or Bharat Biotech, pursuant to which we obtained an
exclusive right and license under certain of Bharat Biotech&#146;s intellectual property rights, with the right to grant sublicenses,
to develop, manufacture and commercialize COVAXIN, a whole-virion inactivated COVID-19 vaccine candidate, in the United States
of America, its territories and possessions. COVAXIN has received an approval for emergency restricted use in India following receipt
of data from the Phase 1 and Phase 2 clinical trials in India. A Phase 3 study is currently ongoing in India and interim data is
expected to be released in March 2021. Notwithstanding receipt of the approval for emergency restricted use in India, Bharat Biotech&#146;s
development efforts in India are in the early stages and remain subject to ongoing clinical trials. Bharat Biotech may be unable
to develop or produce a vaccine that successfully vaccinates against the SARS-CoV-2 virus or emerging variants of the virus, including
the variants that have emerged in South Africa or the United Kingdom. Moreover, subjects receiving COVAXIN in Bharat Biotech&#146;s
clinical trials, as well as patients receiving the vaccine under the emergency restricted use approval in India, may experience
allergic reactions or other adverse events, which could adversely impact on the U.S. market&#146;s perception of the vaccine. Any
of these events could materially impair our ability to develop COVAXIN in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our development efforts with respect to the U.S. market are
in their initial stages, and we may be unable to obtain authorization or approval of COVAXIN in the United States, in a timely
manner, if at all. There have been limited discussions with FDA to date and no Emergency Use Authorization, or EUA, Application
or Investigational New Drug, or IND, Application has been submitted. The FDA may determine that the studies conducted in India
were not done in compliance with FDA regulations, including Good Clinical Practice, or GCP, regulations. For this and other reasons,
the FDA may not accept data from the studies conducted with COVAXIN at clinical trial sites in India and may require us to conduct
clinical studies in the United States before considering an application for an EUA in the United States. Even if we conduct clinical
trials in the United States, we may not be successful in obtaining an EUA from the FDA if our development efforts were to result
in findings relating to a lack of efficacy, safety concerns or other issues. Our inability to obtain an EUA from the FDA could
materially and adversely affect our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As an organization, we have no experience in the development,
manufacturing, distribution or commercialization of a vaccine candidate.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never undertaken the development, manufacturing, distribution
or commercialization of a vaccine candidate, and we may be unable to obtain regulatory authorization or approval in the United
States. Additionally, development of an effective vaccine candidate depends on the success of our and our partner&#146;s manufacturing
capabilities. We have not previously ramped our organization for a commercial launch of any product, and doing so in a pandemic
environment with an urgent, critical global need creates additional challenges such as clinical trials, licensing, distribution
channels, intellectual property disputes or challenges, and the need to establish teams of people with the relevant skills. We
may also face challenges with sourcing a sufficient amount of raw materials to support the demand for a vaccine, including any
potential import issues. We may be unable to effectively create a supply chain for COVAXIN that will adequately support demand.
Furthermore, there are no assurances that any vaccine candidate would be approved or authorized by the FDA at all or for inclusion
in government stockpile programs, which may be material to the commercial success of a vaccine product candidate, in the United
States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The regulatory pathway for COVID-19 vaccine candidates,
including COVAXIN, is continually evolving, and may result in unexpected or unforeseen challenges.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">COVAXIN has moved rapidly through the regulatory review process
for emergency restricted use in India. We cannot predict the speed at which we will be able to obtain authorization or approval
of COVAXIN in the United States, if at all. Evolving or changing plans or priorities at the FDA, including changes based on new
knowledge of COVID-19 and how the disease affects the human body, may significantly affect the regulatory pathway and timeline
for COVAXIN authorization or approval in the United States. The FDA may not accept data from the studies conducted with COVAXIN
at clinical trial sites in India and may require additional clinical trials. Any results from further clinical testing may raise
new questions and require us to redesign proposed clinical trials, including revising proposed endpoints or adding new clinical
trial sites or cohorts of subjects. In addition, the FDA&#146;s analysis of any clinical data may differ from our interpretation
and the FDA may require that we conduct additional analysis or trials. Further, the ongoing Phase 3 trial in India may demonstrate
that the vaccine candidate is ineffective or has an unacceptable safety profile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA has the authority to grant an EUA to allow unapproved
medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when
there are no adequate, approved, and available alternatives. If we are granted an EUA by the FDA for COVAXIN, we would be able
to commercialize it without FDA approval. However, the FDA may revoke the EUA where it is determined that the COVID-19 public health
emergency no longer exists or warrants such authorization, and we cannot predict how long, if ever, an EUA would remain in place.
Such revocation could adversely impact our business in a variety of ways, including if COVAXIN is not yet approved by the FDA and
if we, Bharat Biotech and our manufacturing partners have invested in the supply chain to provide COVAXIN under an EUA in the United
States. In addition, the FDA may revoke or terminate the EUA sooner if, for example, we fail to comply with the conditions of authorization
or other terms of the EUA or if COVAXIN is determined to be less effective or safe than it was initially believed to be. We cannot
predict how long, if ever, an EUA would remain in place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to produce a successful vaccine may be curtailed
by one or more government actions or interventions, which may be more likely during a global health crisis such as COVID-19.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given the significant global impact of the COVID-19
pandemic, it is possible that the U.S. government may take actions that directly or indirectly have the effect of diminishing
some of our rights or opportunities with respect to COVAXIN and the economic value of a COVID-19 vaccine to us could be
limited. In the United States, the Defense Production Act of 1950, as amended, or the Defense Production Act, gives the
United States government rights and authorities that may directly or indirectly diminish our own rights or opportunities with
respect to COVAXIN and the economic value of a COVID-19 vaccine to us could be limited. Our potential third-party service
providers may be impacted by government entities regarding potentially invoking the Defense Production Act or other potential
restrictions to all or a portion of services they might otherwise offer. Government entities imposing restrictions or
limitations on our third-party service providers may require us to obtain alternative service sources for our vaccine
candidate, including COVAXIN. If we are unable to timely enter into alternative arrangements, or if such alternative
arrangements are not available on satisfactory terms, we will experience delays in the development or production of our
vaccine candidate, increased expenses, and delays in potential distribution or commercialization of our vaccine candidate,
when and if approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may need additional funding in order to enable us to
successfully develop COVAXIN, and such funding may not be available on acceptable terms, or at all.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may need additional funding in order to enable us to successfully
develop and obtain FDA authorization or approval and have sufficient capacity to manufacture, commercialize and distribute COVAXIN,
if authorized or approved by the FDA. Such funding may not be available on acceptable terms, or at all. Our commitment of substantial
financial resources and personnel to the joint development of a vaccine candidate may cause delays in or otherwise negatively impact
our other development programs, despite uncertainties surrounding the longevity and extent of COVID-19 as a global health concern.
Our business could be negatively impacted by our allocation of significant resources to a global health threat that is unpredictable
and could rapidly dissipate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we encounter difficulties in obtaining adequate supply
of COVAXIN from Bharat Biotech or third-party manufacturers, our ability to develop and commercialize COVAXIN, if authorized or
approved, would be impaired.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not currently have the capacity
to manufacture COVAXIN, and we do not currently plan to develop any capacity to do so. Bharat Biotech has agreed to provide
to Ocugen all preclinical and clinical data, and to transfer to us certain proprietary technology owned or controlled by
Bharat Biotech, that are necessary for the successful commercial manufacture and supply of COVAXIN to support commercial sale
in the United States, if authorized or approved, including pursuant to an EUA. Until the completion of that technology
transfer and until we are capable and primarily responsible for the manufacture and supply of COVAXIN in the United States
through third parties, Bharat Biotech has the exclusive right to manufacture COVAXIN and we will be wholly dependent on
Bharat Biotech for the manufacture and supply of clinical testing materials required for our development activities and all
of our requirements of commercial quantities of COVAXIN, if authorized or approved. We and Bharat Biotech intend to enter
into supply agreements setting forth the terms of such supply arrangement, but can be no assurance that we will be able to
successfully enter into such agreements. Bharat Biotech has agreed to provide a specified minimum number of doses in calendar
year 2021, but there can be no assurance that they will in fact provide such number of doses, whether due to shortages in
supply, diversion of vaccine resources to other uses deemed more immediate, or other factors. There can be no assurance that
we will be successful in transitioning the manufacture of COVAXIN for the U.S. market from Bharat Biotech to a third-party
manufacturer. If we are unable to obtain adequate supply of COVAXIN, our U.S. development and commercialization efforts would
be impaired. As a result, our business, financial condition and results of operations would be materially adversely
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face significant competition from other pharmaceutical
and biotechnology companies, academic institutions, government agencies, and other research organizations. Our operating results
will suffer if we fail to compete effectively.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of new vaccines is highly
competitive. The competitive landscape of potential COVID-19 vaccines and treatment therapies has been rapidly developing since
the beginning of the COVID-19 pandemic, with several hundreds of companies claiming to be investigating possible candidates and
more than 4,500 studies registered worldwide as investigating COVID-19. We are aware of several competitors developing late-stage
COVID-19 vaccines, including Pfizer Inc. with BioNTech SE, Moderna, Inc., AstraZeneca PLC, Johnson &amp; Johnson/Janssen Biotech,
Inc. and Novavax, Inc. Vaccines developed by Pfizer Inc. with BioNTech SE and Moderna, Inc. have
already been granted EUAs by the FDA. We are also aware of others pharmaceutical companies that are working on inactivated virus-based
COVID-19 vaccines. If the FDA requires us to conduct clinical trials, enrollment in such trials may be impacted given the commercial
availability of other EUA-authorized vaccines. The success or failure of other vaccines, or perceived success or failure, may adversely
impact our ability to obtain any future funding for our joint COVID-19 vaccine development efforts or for us to ultimately commercialize
any vaccine candidate, if authorized or approved by the FDA. In addition, we may not be able to compete effectively if our product
candidate does not satisfy government procurement requirements with respect to biodefense products. If existing vaccines in the
market or if competitors develop and commercialize additional COVID-19 vaccines before we can complete regulatory review and obtain
an EUA or regulatory approval for COVAXIN, or if they develop and commercialize one or more COVID-19 vaccines that are safer, more
effective, have fewer or less severe side effects, have broader market acceptance, are more convenient or are less expensive than
COVAXIN, our business, financial condition and results of operations would be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be successful in maintaining our co-development
relationship with Bharat Biotech, which would adversely affect our ability to develop and commercialize COVAXIN.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have licensed the rights to develop COVAXIN in the United
States from Bharat Biotech. Our co-development efforts began recently. The success of this licensing and co-development arrangement
will depend heavily on the efforts and activities of Bharat Biotech. Other than as specifically set forth in the COVAXIN Agreement,
we will have limited control over the amount and timing of resources that Bharat Biotech dedicates to the co-development of and
manufacture of supply for COVAXIN in the U.S. market. We also have limited or no control over Bharat Biotech&#146;s activities
with respect to COVAXIN in India. If Bharat Biotech were to fail to successfully complete the ongoing Phase&#160;3 clinical trial
of COVAXIN, or were to fail to report safety data in accordance with regulatory requirements, our ability to develop COVAXIN in
the United States would be impaired. Moreover, any disagreements between us and Bharat Biotech could lead to delays in the development
process or manufacturing of COVAXIN, and such delays may impair our ability to obtain an EUA or approval for COVAXIN. Under certain
circumstances, disagreements with Bharat Biotech could also lead to termination of the COVAXIN Agreement. Any such termination
would prevent us from developing COVAXIN for the U.S. market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d)&#160;Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are being filed herewith:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; width: 8%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit<br />
No.</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="white-space: nowrap; text-align: center; width: 90%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Document</b></span></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm215707d2_ex5-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">5.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm215707d2_ex5-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Opinion of Troutman Pepper Hamilton Sanders LLP.</span></a></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm215707d2_ex10-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm215707d2_ex10-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Form&#160;of Securities Purchase Agreement.</span></a></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><a href="tm215707d2_ex5-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">23.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm215707d2_ex5-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Consent of Troutman Pepper Hamilton Sanders LLP (included in Exhibit&#160;5.1).</span></a></td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: February&#160;9, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif">OCUGEN,&#160;INC.</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Shankar Musunuri</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Name: Shankar Musunuri</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Title: Chief Executive Officer and Chairman</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2OnI1JPAyqYgsQiS63XKMJd2R2c3qkXrLNiUaBubvfHOEmIg1rXSDDKdFkUOJbdcoh1BgjYzmgl6RbbYp+FrgVVvHyrhh/IEZeQY9k0xnZ78flL22WKUgk1DOw1j6Jo0kHHYi+N4zMrWu0DitGlCmggNTxxqd4tf4oVRPMtS+BqcjstVkUoimcjy/IZZRDHvq1YP4ZiHPMxFMhgjEmunefW3u1lELywZb72VH9J/BB9q/SRQ= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm215707d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Troutman Pepper Hamilton Sanders LLP</FONT></TD>
    <TD ROWSPAN="4" STYLE="text-align: right; width: 50%">&nbsp;<IMG SRC="tm215707d2_ex5-1img01.jpg" ALT=""></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3000 Two Logan Square, Eighteenth and Arch Streets</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19103-2799</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">troutman.com</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: rgb(0,145,218) 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: rgb(0,145,218) 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 25%">&nbsp;</TD><TD STYLE="width: 40%; text-align: left"></TD><TD STYLE="text-align: justify; width: 35%">February 9, 2021</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ocugen,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">263 Great Valley Parkway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Malvern, Pennsylvania 19355</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">We
are acting as counsel to Ocugen,&nbsp;Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with the public
offering of 3,000,000 shares of the common stock, par value $0.01 per share of the Company (the &ldquo;<B>Shares</B>&rdquo;) to
be sold by the Company pursuant to a prospectus supplement, dated February&nbsp;7, 2021, and the accompanying base prospectus,
dated May&nbsp;5, 2020 (such documents, collectively, the &ldquo;<B>Prospectus</B>&rdquo;) that form part of the Company&rsquo;s
effective registration statement on Form&nbsp;S-3 (File No.&nbsp;333-237456) (the &ldquo;<B>Registration Statement</B>&rdquo;).
This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item </FONT>601(b)(5)&nbsp;of
Regulation S-K, 17 C.F.R. &sect; 229.601(b)(5), in connection with the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">For
purposes of this opinion letter, we have examined copies of such agreements, instruments and documents as we have deemed an appropriate
basis on which to render the opinion hereinafter expressed. In our examination of the aforesaid documents, we have assumed the
genuineness of all signatures, the legal capacity of all natural persons, the accuracy and completeness of all documents submitted
to us, the authenticity of all original documents, and the conformity to authentic original documents of all documents submitted
to us as copies (including pdfs.). As to all matters of fact, we have relied on the representations and statements of fact made
in the documents so reviewed, and we have not independently established the facts so relied on. This opinion letter is given, and
all statements herein are made, in the context of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This
opinion letter is based as to matters of law solely on the General Corporation Law of the State of Delaware, as amended. We express
no opinion herein as to any other statutes, rules&nbsp;or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Based
upon, subject to and limited by the foregoing, we are of the opinion that as of the date hereof f</FONT>ollowing (i)&nbsp;execution
and delivery by the Company of the Securities Purchase Agreement, dated February&nbsp;7, 2021, by and among the Company and certain
investors named therein (the &ldquo;<B>Agreement</B>&rdquo;), (ii)&nbsp;issuance of the Shares pursuant to the terms of the Agreement
and the due registration on the books of the transfer agent and registrar therefor, and (iii)&nbsp;receipt by the Company of the
consideration for the Shares (not less than par value) in the circumstances contemplated by the Agreement, the Shares will be validly
issued, fully paid, and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD ROWSPAN="4" STYLE="width: 50%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 64px; width: 138px"></FONT>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD ROWSPAN="4" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ocugen,&nbsp;Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February&nbsp;9, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page&nbsp;2</FONT></TD></TR>
<TR>
    <TD STYLE="border-bottom: rgb(0,145,218) 1pt solid; vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: rgb(0,145,218) 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This
opinion letter has been prepared for use in connection with the filing by the Company of a Current Report on Form&nbsp;8-K relating
to the offer and sale of the Shares, which Form&nbsp;8-K will be incorporated by reference into the Registration Statement and
Prospectus, and speaks as of the date hereof. We assume no obligation to advise you of any changes in the foregoing subsequent
to the delivery of this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">We
hereby consent to the filing of this opinion letter as Exhibit&nbsp;5.1 to the above-described Form&nbsp;8-K and to the reference
to this firm under the caption &ldquo;Legal Matters&rdquo; in the Prospectus. In giving this consent, we do not thereby admit that
we are an &ldquo;expert&rdquo; within the meaning of the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ TROUTMAN PEPPER HAMILTON SANDERS LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TROUTMAN PEPPER HAMILTON SANDERS LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>tm215707d2_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of February&nbsp;7, 2021, between Ocugen,&nbsp;Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages&nbsp;hereto (each, including its successors
and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to
the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act
(as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires
to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,&nbsp;IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&nbsp;I.</B></FONT><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section&nbsp;1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>At
Market Issuance Sales Agreement</U>&rdquo; means that certain At Market Issuance Sales Agreement dated August&nbsp;14, 2020 by
and between the Company and Cantor Fitzgerald&nbsp;&amp; Co. and Oppenheimer&nbsp;&amp; Co. Inc., as in effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to
be authorized or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential
employee&rdquo;&nbsp; or any other similar orders or restrictions or the closure of any physical branch locations at the direction
of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks
in The City of New York generally are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Shares pursuant to Section&nbsp;2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i)&nbsp;the Purchasers&rsquo; obligations to pay the Subscription Amount and
(ii)&nbsp;the Company&rsquo;s obligations to deliver the Shares, in each case, have been satisfied or waived, but in no event later
than the second (2<SUP>nd</SUP>) Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Troutman Pepper Hamilton Sanders&nbsp;LLP, with offices located at 3000 Two Logan Square, Eighteenth and
Arch Streets, Philadelphia, PA 19103.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i)&nbsp;if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m.&nbsp;(New York
City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m.&nbsp;(New York City time) on the Trading Day
immediately following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii)&nbsp;if
this Agreement is signed between midnight (New York City time) and 9:00 a.m.&nbsp;(New York City time) on any Trading Day, no later
than 9:01 a.m.&nbsp;(New York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(r).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a)&nbsp;securities to directors, officers, employees and consultants of the Company
pursuant to employee benefit plans, equity incentive plans or other employee compensation plans existing on the date hereof and
as described in the Prospectus, (b)&nbsp;any shares of Common Stock upon exercise of the warrants to the Placement Agent, if applicable,
and/or shares of Common Stock upon the exercise or exchange of or conversion of securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended
since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or
conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such
securities, and (c)&nbsp;securities issued in connection with any joint venture, commercial or collaborative relationship, or the </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">acquisition or license by the Company of the securities, business, property or other assets of another person, provided that such
issuance is approved by the majority of the disinterested directors of the Company, and provided that such securities are issued
as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights that require or permit the
filing of any registration statement in connection therewith during the prohibition period in Section&nbsp;4.12(a)&nbsp;herein,
and (d)&nbsp;issuances to one or more lenders in connection with the Company&rsquo;s entry into a non-convertible debt financing
transaction, provided that such issuance set forth in clause (d)&nbsp;shall only be in the form of warrants to purchase shares
of Common Stock and the shares of Common Stock underlying such warrants shall be &ldquo;restricted securities&rdquo; (as defined
in Rule&nbsp;144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith during the prohibition period in Section&nbsp;4.12(a)&nbsp;herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(gg).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(z).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(o).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section&nbsp;3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $7.65, subject to adjustment for reverse and forward stock splits, stock dividends, stock
combinations and other similar transactions of the Common Stock that occur after the date of this Agreement and prior to the Closing
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright&nbsp;&amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final base prospectus filed for the Registration Statement, including all information, documents and exhibits filed with
or incorporated by reference into such base prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule&nbsp;424(b)&nbsp;of the Securities Act that is
filed with the Commission and delivered by the Company to each Purchaser at the Closing, including all information, documents and
exhibits filed with or incorporated by reference into such supplement to the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission (File No.&nbsp;333-237456), including all information,
documents and exhibits filed with or incorporated by reference into such registration statement, which registers the sale of the
Shares to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;144</U>&rdquo;
means Rule&nbsp;144 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted
from time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;424</U>&rdquo;
means Rule&nbsp;424 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted
from time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule&nbsp;200 of Regulation SHO under the Exchange Act (but
shall not be deemed to include locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares purchased hereunder as specified below
such Purchaser&rsquo;s name on the signature page&nbsp;of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company set forth on Exhibit&nbsp;21.1 of the Company&rsquo;s most recently filed Annual Report on
Form&nbsp;10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or
the New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Broadridge Corporate Issuer Solutions,&nbsp;Inc., the current transfer agent of the Company and any successor
transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&nbsp;II.</B></FONT><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers,
severally and not jointly, agree to purchase, up to an aggregate of $22.95 million of Shares. Each Purchaser&rsquo;s Subscription
Amount as set forth on the signature page&nbsp;hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus
Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) settlement with the Company or its designees. The Company shall deliver to each Purchaser
its respective Shares and the Company and each Purchaser shall deliver the other items set forth in Section&nbsp;2.2 deliverable
at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at
the offices of the Placement Agent or such other location as the parties shall mutually agree. Unless otherwise directed by the
Placement Agent, settlement of the Shares shall occur via DVP (i.e., on the Closing Date, the Company shall issue the Shares registered
in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to the account(s)&nbsp;at the Placement
Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such
Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer
to the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in a form reasonably acceptable to the Placement
Agent and Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Company&rsquo;s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">subject
to the last sentence of Section&nbsp;2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer
Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
Shares equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such
Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule&nbsp;172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">such
Purchaser&rsquo;s Subscription Amount, which shall be made available for DVP settlement with the Company or its designees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing
Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b)&nbsp;of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
delivery by the Company of the items set forth in Section&nbsp;2.2(a)&nbsp;of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are
reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national
or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in
each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Shares at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&nbsp;III.</B></FONT><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. The Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsidiaries</U>.
The Subsidiaries are the Company&rsquo;s only significant subsidiaries (as such term is defined in Rule&nbsp;1.02 of Regulation
S-X promulgated by the Commission). Except as set forth in the Prospectus or the Prospectus Supplement, the Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the
issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free
of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted as described in the
SEC Reports. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate
or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is
duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which
the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be
so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i)&nbsp;a material
adverse effect on the legality, validity or enforceability of any Transaction Document, (ii)&nbsp;a material adverse effect on
the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries,
taken as a whole, or (iii)&nbsp;a material adverse effect on the </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Company&rsquo;s
ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii)&nbsp;or
(iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking,
limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents. The execution and delivery of this Agreement and each of the other
Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly
authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors
or the Company&rsquo;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This
Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by
the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation
of the Company enforceable against the Company in accordance with its terms, except (i)&nbsp;as limited by general equitable principles
and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of
creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable
law and public policy considerations in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Shares and the consummation by it of the transactions contemplated hereby and
thereby do not and will not (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a
default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien
upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment,
anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement,
credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which
the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected,
or (iii)&nbsp;subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject
(including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary
is bound or affected; except in the case of each of clauses (ii)&nbsp;and (iii), such as could not have or reasonably be expected
to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">registration
with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution,
delivery and performance by the Company of the Transaction Documents, other than: (i)&nbsp;the filings required pursuant to Section&nbsp;4.4
of this Agreement, (ii)&nbsp;the filing with the Commission of the Prospectus Supplement, (iii)&nbsp;application(s)&nbsp;to each
applicable Trading Market for the listing of the Shares for trading thereon in the time and manner required thereby, and (iv)&nbsp;such
filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Issuance
of the Shares; Registration</U>. The Shares are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the
Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable
pursuant to this Agreement. The Company has prepared and filed the Registration Statement in conformity with the requirements of
the Securities Act, which became effective on&nbsp;May&nbsp;5, 2020, including the Prospectus, and such amendments and supplements
thereto as may have been required to the date of this Agreement. The Company was at the time of the filing of the Registration
Statement eligible to use Form&nbsp;S-3. The Company is eligible to use Form&nbsp;S-3 under the Securities Act and it meets the
transaction requirements as set forth in General Instruction I.B.1 of Form&nbsp;S-3. The Registration Statement is effective under
the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or
preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules&nbsp;and regulations
of the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule&nbsp;424(b). At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration
Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements
thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will
conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.
The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and nonassessable and,
other than as disclosed in the SEC Reports, are not subject to any preemptive rights, rights of first refusal or similar rights.
The Company has an authorized, issued and outstanding capitalization as set forth in the SEC Reports as of the dates referred to
therein (other than the grant of additional options under the Company&rsquo;s existing equity incentive or stock option plans,
or changes in the number of outstanding shares of Common Stock of the Company due to (i)&nbsp;the issuance of shares upon the exercise
or conversion of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof and (ii)&nbsp;the
issuance of shares of Common Stock pursuant to the At Market Issuance Sales Agreement) and such </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">authorized
capital stock conforms in all material respects to the description thereof set forth in the SEC Reports. The description of the
securities of the Company in the SEC Reports is complete and accurate in all material respects. Except as disclosed in or contemplated
by the SEC Reports, (i)&nbsp;no Person has the right, contractual or otherwise, to cause the Company to issue or sell to such
Person any Common Stock or shares of any other capital stock or other securities of the Company (other than outstanding options
or warrants to purchase Common Stock or options or other equity securities that may be granted from time to time under the Company&rsquo;s
equity incentive plans which are disclosed in the SEC Reports) and (ii)&nbsp;no Person has any preemptive rights, resale rights,
rights of first refusal, rights of co-sale, or any other rights (whether pursuant to a &ldquo;poison pill&rdquo; provision or
otherwise) to purchase any Common Stock or shares of any other capital stock or other securities of the Company. The issuance
and sale of the Shares will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to
any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with
any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of
securities by the Company or any Subsidiary. There are no stockholders agreements, voting agreements or other similar agreements
with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between
or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;thereof
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus
and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis
or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such
extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities
Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule&nbsp;144(i)&nbsp;under
the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with the
requirements of the Securities Act and the Exchange Act as in effect at the time of filing. Such financial statements have been
prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods
involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and
except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit
adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Subsequent to the respective dates as of which information is given
in the SEC Reports, (i)&nbsp;there has been no event, occurrence or development that has had or that could reasonably be expected
to result in a Material Adverse Effect, (ii)&nbsp;the Company has not incurred any liabilities (contingent or otherwise) which
is material to the Company and the Subsidiaries taken as a whole, (iii)&nbsp;the Company has not altered its method of accounting,
(iv)&nbsp;the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased,
redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v)&nbsp;the Company has not issued any
equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does
not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Shares
contemplated by this Agreement or as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or development
has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective
businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company
under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at
least one (1)&nbsp;Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;)
which would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither
the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim
of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been,
and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company
or any current or former director or officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of
the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any restrictive covenant in favor of any third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compliance</U>.
Neither the Company nor any Subsidiary: (i)&nbsp;is in default under or in violation of (and no event has occurred that has not
been waived that, with </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">notice
or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary
received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such
default or violation has been waived), (ii)&nbsp;is in violation of any judgment, decree or order of any court, arbitrator or
other governmental authority or (iii)&nbsp;is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all applicable foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as
could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Title
to Assets</U>. The Company and the Subsidiaries do not own any real property. The Company and Subsidiaries have good and marketable
title in all personal property owned by them that is material to the business of the Company and the Subsidiaries (other than intellectual
property, which is addressed in Section&nbsp;3.1(o)), in each case free and clear of all Liens, except for (i)&nbsp;Liens as do
not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such
property by the Company and the Subsidiaries, and (ii)&nbsp;Liens for the payment of federal, state or other taxes, for which appropriate
reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties.
Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting
and enforceable leases with which the Company and the Subsidiaries are in compliance, except where the failure to be in compliance
would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>. The Company and its Subsidiaries own, possess, license or have other rights to use, or can acquire on reasonable
terms a license or other rights to use, all foreign and domestic patents, patent applications, trade and service marks, trade and
service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology,&nbsp;Internet domain names,
know-how and other intellectual property (collectively, the &ldquo;<U>Intellectual Property</U>&rdquo;), necessary for the conduct
of their respective businesses as currently conducted as described in the SEC Reports except to the extent that the failure to
own, possess, license or otherwise hold adequate rights to use such Intellectual Property would not, individually or in the aggregate,
have a Material Adverse Effect. Except as disclosed in the SEC Reports (i)&nbsp;to the Company&rsquo;s knowledge, there are no
rights of third parties to any such Intellectual Property owned by the Company and its Subsidiaries; (ii)&nbsp;to the Company&rsquo;s
knowledge, there is no infringement by third parties of any such Intellectual Property; (iii)&nbsp;there is no pending or, to the
Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the Company&rsquo;s and its Subsidiaries&rsquo;
rights in or to any such Intellectual Property, and the Company is unaware of any facts which could form a reasonable basis for
any such action, suit, proceeding or claim; (iv)&nbsp;there is no pending or, to the Company&rsquo;s knowledge, threatened action,
suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property; (v)&nbsp;there is no pending
or, to the Company&rsquo;s knowledge, threatened action, suit, </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">proceeding
or claim by others that the Company and its Subsidiaries infringe or otherwise violate any patent, trademark, copyright, trade
secret or other proprietary rights of others; (vi)&nbsp;to the Company&rsquo;s knowledge, there is no third-party U.S. patent or
published U.S. patent application which contains claims for which an Interference Proceeding (as defined in 35 U.S.C. &sect; 135)
has been commenced against any patent or patent application described in the SEC Reports as being owned by or licensed to the Company;
and (vii)&nbsp;the Company and its Subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property
has been licensed to the Company or such Subsidiary, and all such agreements are in full force and effect, except, in the case
of any of clauses (i)-(vii)&nbsp;above, for any such infringement by third parties or any such pending or threatened suit, action,
proceeding or claim as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the
Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without
a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transactions
With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company or
any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party
to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case
in excess of $120,000 other than for (i)&nbsp;payment of salary or consulting fees for services rendered, (ii)&nbsp;reimbursement
for expenses incurred on behalf of the Company and (iii)&nbsp;other employee benefits, including equity incentive agreements under
any equity incentive plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance in all material respects with any and all
applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable
rules&nbsp;and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing
Date. The Company and the Subsidiaries maintain a system of internal accounting controls designed to provide reasonable assurance
that: (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">general or specific authorization, and (iv)&nbsp;the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined
in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls
and procedures to provide reasonable assurance that information required to be disclosed by the Company in the reports it files
or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules&nbsp;and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures
of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange
Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under
the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based
on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over
financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected,
or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Fees</U>. Except as set forth in the Prospectus Supplement, no brokerage or finder&rsquo;s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank
or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in
this Section&nbsp;that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not
be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Registration
Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act
of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. Except as disclosed in the SEC Reports, the Company has not, in the 12 months preceding the date
hereof, received notice from any Trading Market on which the Common Stock is </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">or has been
listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading
Market. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established
clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established
clearing corporation) in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and
the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company&rsquo;s issuance of the Shares and the Purchasers&rsquo; ownership of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed
in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, is true and correct
and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated
by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and
agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby
other than those specifically set forth in Section&nbsp;3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section&nbsp;3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Shares to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Shares hereunder, (i)&nbsp;the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii)&nbsp;the Company&rsquo;s assets do not constitute unreasonably small capital
to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii)&nbsp;the current cash flow of the Company, together with the proceeds the Company would receive, were it to
liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts
on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond
its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect
of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization
or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. The SEC Reports
set forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which
the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x)&nbsp;any
liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
course of business), (y)&nbsp;all guaranties, endorsements and other contingent obligations in respect of indebtedness of others,
whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except
guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of
business; and (z)&nbsp;the present value of any lease payments in excess of $50,000 due under leases required to be capitalized
in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Tax
Status</U>. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have been
required to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and
are not being contested in good faith, except where the failure to so file or pay would not reasonably be expected to have a Material
Adverse Effect. Except as otherwise disclosed in or contemplated by the SEC Reports, no tax deficiency has been determined adversely
to the Company or any of its Subsidiaries which has had, or would reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect. The Company has no knowledge of any federal, state or other governmental tax deficiency, penalty or
assessment which has been or might be asserted or threatened against it which would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
or other person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)&nbsp;made
any unlawful payment to foreign or domestic </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">government
officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii)&nbsp;failed to
disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the
Company is aware) which is in violation of law, or (iv)&nbsp;violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Accountants</U>.
The Company&rsquo;s independent registered public accounting firm is Ernst&nbsp;&amp; Young LLP. To the knowledge of the Company,
such accounting firm (i)&nbsp;is a registered public accounting firm as required by the Exchange Act and (ii)&nbsp;shall express
its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ended
December&nbsp;31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Shares</U>. The Company acknowledges and agrees that each of the Purchasers is acting
solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in
any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given
by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Shares. The Company further represents to each
Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has been based solely
on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections&nbsp;3.2(f)&nbsp;and 4.14 hereof), it is understood and acknowledged by the Company that: (i)&nbsp;none of
the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long
and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to
hold the Shares for any specified term; (ii)&nbsp;past or future open market or other transactions by any Purchaser, specifically
including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future
private placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii)&nbsp;any
Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly,
presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv)&nbsp;each Purchaser shall not be deemed to have
any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company
further understands and acknowledges that (y)&nbsp;one or more Purchasers may engage in hedging activities at various times during
the period that the Shares are outstanding, and (z)&nbsp;such hedging activities (if any) could reduce the value of the existing
stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted.&nbsp; The
Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i)&nbsp;taken, directly or
indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Shares, (ii)&nbsp;sold, bid for, purchased, or, paid any compensation for
soliciting purchases of, any of the Shares, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting
another to purchase the Shares, other than, in the case of clauses (ii)&nbsp;and (iii), compensation paid to the Company&rsquo;s
placement agent in connection with the placement of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Regulatory
Permits</U>. Except as disclosed in the SEC Reports, the Company and its Subsidiaries have made all filings, applications and submissions
required by, possesses and is operating in compliance with, all approvals, licenses, certificates, certifications, clearances,
consents, grants, exemptions, marks, notifications, orders, permits and other authorizations issued by, the appropriate federal,
state or foreign governmental authority (including, without limitation, the United States Food and Drug Administration (the &ldquo;<U>FDA</U>&rdquo;),
the United States Drug Enforcement Administration or any other foreign, federal, state, provincial, court or local government or
regulatory authorities including self-regulatory organizations engaged in the regulation of clinical trials, pharmaceuticals, biologics
or biohazardous substances or materials) necessary for the ownership or lease of their respective properties or to conduct its
businesses as currently conducted as described in the SEC Reports (collectively, &ldquo;<U>Permits</U>&rdquo;), except for such
Permits the failure of which to possess, obtain or make the same would not reasonably be expected to have a Material Adverse Effect;
the Company and its Subsidiaries are in compliance with the terms and conditions of all such Permits, except where the failure
to be in compliance would not reasonably be expected to have a Material Adverse Effect; all of the Permits are valid and in full
force and effect, except where any invalidity, individually or in the aggregate, would not be reasonably expected to have a Material
Adverse Effect; and neither the Company nor any of its Subsidiaries has received any written notice relating to the limitation,
revocation, cancellation, suspension, modification or non-renewal of any such Permit which, singly or in the aggregate, if the
subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a Material Adverse Effect, or has any
reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course. To the
extent required by applicable laws and regulations of the FDA, the Company or the applicable Subsidiary has submitted to the FDA
an Investigational New Drug Application or amendment or supplement thereto for each clinical trial it has conducted or sponsored
or is conducting or sponsoring; all such submissions were in material compliance with applicable laws and rules&nbsp;and regulations
when submitted and no material deficiencies have been asserted by the FDA with respect to any such submissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)&nbsp;&nbsp;&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Regulatory
Filings</U>. Except as disclosed in the SEC Reports, neither the Company nor any of its Subsidiaries has failed to file with the
applicable governmental authorities (including, without limitation, the FDA, or any foreign, federal, state, provincial or local
governmental authority performing functions similar to those performed by the FDA) any required filing, declaration, listing,
registration, report or submission, except for such failures that, individually or in the aggregate, would not reasonably be expected
to have a Material Adverse Effect; except as disclosed in the SEC Reports, all such filings, declarations, listings, registrations,
reports or submissions were in compliance with </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">applicable
laws when filed and no deficiencies have been asserted by any applicable regulatory authority with respect to any such filings,
declarations, listings, registrations, reports or submissions, except for any deficiencies that, individually or in the aggregate,
would not reasonably be expected to have a Material Adverse Effect. The Company has operated and currently is, in all material
respects, in compliance with the United States Federal Food, Drug, and Cosmetic Act, all applicable rules&nbsp;and regulations
of the FDA and other federal, state, local and foreign governmental authority exercising comparable authority. The Company has
no knowledge of any studies, tests or trials not described in the SEC Repots the results of which reasonably call into question
in any material respect the results of the studies, tests and trials described in the SEC Reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Clinical
Studies</U>. The preclinical studies and tests and clinical trials described in the SEC Reports being conducted by or on behalf
of the Company were, and, if still pending, are being conducted in all material respects in accordance with the experimental protocols,
procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates
comparable to those being developed by the Company; the descriptions of such studies, tests and trials, and the results thereof,
contained in the SEC Reports are accurate and complete in all material respects; the Company is not aware of any tests, studies
or trials not described in the SEC Reports, the results of which reasonably call into question the results of the tests, studies
and trials described in the SEC Reports; and the Company has not received any written notice or correspondence from the FDA or
any foreign, state or local governmental authority exercising comparable authority or any institutional review board or comparable
authority requiring the termination, suspension, clinical hold or material modification of any tests, studies or trials that are
described or referred to in the SEC Reports.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option or equity incentive plans was
granted (i)&nbsp;in accordance with the terms of the Company&rsquo;s applicable stock option or equity incentive plan and (ii)&nbsp;with
an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered
granted under GAAP and applicable law. No stock option granted under the Company&rsquo;s stock option or equity incentive plans
has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly
grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement
of material information regarding the Company or its Subsidiaries or their financial results or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act
of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
 &ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%)
or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules&nbsp;and regulations thereunder (collectively, the &ldquo;<U>Money
Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of
the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they
shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and
performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction
Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with
the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except: (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar
as indemnification and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Shares as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Shares (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Shares pursuant to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">the Registration
Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Shares
hereunder in the ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Purchaser
Status</U>. At the time such Purchaser was offered the Shares, it was, and as of the date hereof it is, either: (i)&nbsp;an &ldquo;accredited
investor&rdquo; as defined in Rule&nbsp;501(a)(1), (a)(2), (a)(3), (a)(7)&nbsp;or (a)(8)&nbsp;under the Securities Act or (ii)&nbsp;a
 &ldquo;qualified institutional buyer&rdquo; as defined in Rule&nbsp;144A(a)&nbsp;under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Shares, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Shares and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i)&nbsp;the opportunity to ask such questions as
it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of
the offering of the Shares and the merits and risks of investing in the Shares; (ii)&nbsp;access to information about the Company
and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate
its investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company possesses or can acquire
without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&nbsp;
Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such
Purchaser with any information or advice with respect to the Shares nor is such information or advice necessary or desired.&nbsp;
Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Shares
and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser
agrees need not be provided to it.&nbsp; In connection with the issuance of the Shares to such Purchaser, neither the Placement
Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting
forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Purchaser&rsquo;s
assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager
that made the investment decision to purchase the Shares covered by this Agreement. Other than to other Persons party to this Agreement
or to such Purchaser&rsquo;s representatives that are bound by confidentiality obligations, including, without limitation, its
officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality
of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude
any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company acknowledges
and agrees that the representations contained in this Section&nbsp;3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this
Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt,
nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing
shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&nbsp;IV.</B></FONT><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Furnishing
of Information</U>. Until the time that no Purchaser owns Shares, the Company covenants to timely file (or obtain extensions in
respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof
pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act; provided,
however, that this covenant shall not prevent a sale, merger or similar transaction involving the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Shares for purposes of the rules&nbsp;and
regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a)&nbsp;by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form&nbsp;8-K, including the Transaction Documents
as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press
release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered
to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or
agents in connection </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the
Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or
oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates
on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and each
Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby,
and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement (other
than press releases or public statements that are consistent with the disclosures included in the press release or Current Report
on Form&nbsp;8-K described in the first sentence of this Section&nbsp;4.4, or required filings with the Commission) without the
prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of the Placement
Agent, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if
such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice
of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of
any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market,
without the prior written consent of such Purchaser, except (a)&nbsp;as required by federal securities law in connection with
the filing of final Transaction Documents with the Commission and (b)&nbsp;to the extent such disclosure is required by law or
Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted
under this clause (b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Shares
under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section&nbsp;4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably
believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt
of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that
each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent
that the Company or any Person acting on its behalf delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s
consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company,
any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis
of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that
any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">public information
regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form&nbsp;8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Shares hereunder for the purposes set forth in the
Prospectus Supplement and shall not use such proceeds: (a)&nbsp;for the satisfaction of any portion of the Company&rsquo;s debt
(other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b)&nbsp;for
the redemption of any Common Stock or Common Stock Equivalents, (c)&nbsp;for the settlement of any outstanding litigation or (d)&nbsp;in
violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section&nbsp;4.8, the Company will indemnify and hold each Purchaser and its
directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers,
shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding
such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and actual, reasonable and documented attorneys&rsquo; fees and costs of investigation
that any such Purchaser Party may suffer or incur as a result of or relating to (a)&nbsp;any breach of any of the representations,
warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b)&nbsp;any
action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder
of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction
Documents (unless such action is based upon a breach of such Purchaser Party&rsquo;s representations, warranties or covenants under
the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations
by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially
determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party
in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company
in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Purchaser Party. To the extent that a Purchaser Party fails to provide timely notice of a claim for indemnity under this
Section&nbsp;4.8, and such failure materially prejudices the Company&rsquo;s ability to defend against such claim, the Company
shall have no obligation under this Section&nbsp;4.8 to indemnify the Purchaser Party for the claim (or portion thereof) that was
so affected. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense
thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (x)&nbsp;the
employment thereof has been specifically authorized by the Company in writing, (y)&nbsp;the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (z)&nbsp;in such action there is, in the reasonable opinion of counsel,
a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which
case the Company </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">shall be responsible
for the actual, reasonable and documented fees and expenses of no more than one such separate counsel. The Company will not be
liable to any Purchaser Party under this Agreement (1)&nbsp;for any settlement by a Purchaser Party effected without the Company&rsquo;s
prior written consent, which shall not be unreasonably withheld or delayed; or (2)&nbsp;to the extent, but only to the extent that
a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties,
covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification
required by this Section&nbsp;4.8 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any
cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject
to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Listing
of Common Stock</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of the
Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply
to list or quote all of the Shares on such Trading Market and promptly use commercially reasonable efforts to secure the listing
of all of the Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded
on any other Trading Market, it will then include in such application all of the Shares, and will take such other action as is
reasonably necessary to cause all of the Shares to be listed or quoted on such other Trading Market as promptly as possible. The
Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market
and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules&nbsp;of
the Trading Market. For so long as the Company maintains a listing or quotation of the Common Stock on a Trading Market, the Company
agrees to use commercially reasonable efforts to maintain the eligibility of the Common Stock for electronic transfer through the
Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees
to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer; provided,
however, that this Section&nbsp;4.10 shall not prevent a sale, merger or similar transaction involving the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsequent
Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">From
the date hereof until fourteen (14) days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, this Section&nbsp;4.12 shall not apply in respect of (i)&nbsp;an Exempt Issuance, (ii)&nbsp;any sales of shares
of Common Stock pursuant to the At Market Issuance Sales Agreement or (iii)&nbsp;any other sales of Common Stock at a price per
share equal to $9.5625 or greater.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to such Transaction Documents. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to
treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect
to the purchase, disposition or voting of Shares or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending
at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section&nbsp;4.4.<FONT>&nbsp; </FONT>Each Purchaser, severally and not jointly with
the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed
by the Company pursuant to the initial press release as described in Section&nbsp;4.4, such Purchaser will maintain the confidentiality
of the existence and terms of this transaction.&nbsp; N<FONT>otwithstanding the foregoing, and notwithstanding
anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i)&nbsp;no Purchaser
makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the
Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial
press release as described in Section&nbsp;4.4, (ii)&nbsp;no Purchaser shall be restricted or prohibited from effecting any transactions
in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated
by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.4 and (iii)&nbsp;no
Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries
after the issuance of the initial press release as described in Section&nbsp;4.4.&nbsp; </FONT>Notwithstanding the foregoing, in
the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions
of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to
the portion of assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Sales
During Pre-Settlement Period</U>. Notwithstanding anything herein to the contrary, if at any time on or after the time of execution
of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing
(the &ldquo;<U>Pre-Settlement Period</U>&rdquo;), such Purchaser sells to any Person all, or any portion, of any shares of Common
Stock to be issued hereunder to such Purchaser at the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such
Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed
to be unconditionally bound to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares to such Purchaser
at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to
the Company&rsquo;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that the Company
hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether
or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision
to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such
sale, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&nbsp;V.</B></FONT><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination</U>.&nbsp;
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing
has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent
fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company),
stamp taxes and other taxes (excluding any income or sales taxes) and duties levied in connection with the delivery of any Shares
to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered
via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages&nbsp;attached
hereto at or prior to 5:30 p.m.&nbsp;(New York City time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission,
if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as
set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York
City time) on any Trading Day, (c)&nbsp;the second (2<SUP>nd</SUP>)Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given.
The address for such notices and communications shall be as set forth on the signature pages&nbsp;attached hereto. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">public information
regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and Purchasers which purchased (or, prior to the Closing, agreed to purchase) at least
50.1% in interest of the Shares based on the initial Subscription Amounts hereunder or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately
and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group
of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this
Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any
manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely
affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall
require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section&nbsp;5.5
shall be binding upon each Purchaser and holder of Shares and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to
whom such Purchaser assigns or transfers any Shares, provided that such transferee agrees in writing to be bound, with respect
to the transferred Shares, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in Section&nbsp;3.1 and the representations and warranties of the Purchasers in Section&nbsp;3.2. This Agreement is
intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.8 and this Section&nbsp;5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New
York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction
of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Action or Proceeding. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at
the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section&nbsp;4.8, the prevailing party in such Action or
Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo;
signature page&nbsp;were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand
or election in whole or in part without prejudice to its future actions and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Replacement
of Shares</U>. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu
of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the
Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation
the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each
Purchaser and its respective counsel have chosen to communicate with the Company through the legal counsel of the Placement Agent.
The legal counsel of the Placement Agent does not represent any of the Purchasers and only represents the Placement Agent. The
Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company
and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each
provision contained in this Agreement and in each other Transaction Document is </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">between the Company
and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc.</U></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If the last or appointed
day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such
action may be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the
drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition,
each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment
for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that
occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,&nbsp;IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages&nbsp;Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>Ocugen,&nbsp;Inc.</B></FONT> &nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address for Notice</U>:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 3%">By:</TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
<TD STYLE="width: 49%">Fax:</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>Name:</TD>
    <TD>&nbsp;</TD>
<TD>E-mail:</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>Title:</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">With a copy to (which shall not constitute notice):&nbsp; &nbsp; &nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO OCGN SECURITIES
PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser: ______________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature
of Authorized Signatory of Purchaser</I></FONT>: _________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Facsimile of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Shares to Purchaser (if not same as
address for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: ____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;Notwithstanding anything contained in
this Agreement to the contrary, by checking this box (i)&nbsp;the obligations of the above-signed to purchase the securities set
forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such
securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)&nbsp;the Closing
shall occur by the second (2nd) Trading Day following the date of this Agreement and (iii)&nbsp;any condition to Closing contemplated
by this Agreement (but prior to being disregarded by clause (i)&nbsp;above) that required delivery by the Company or the above-signed
of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall
instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument,
certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ocgn-20210207.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa+BubOdzZR+aYkxtmB5bckaPyEjHmro+i8MC2xGoekA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:ocgn="http://deitaxonomy.com/20210207" elementFormDefault="qualified" targetNamespace="http://deitaxonomy.com/20210207">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://deitaxonomy.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ocgn-20210207_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ocgn-20210207_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ocgn-20210207_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ocgn-20210207_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://deitaxonomy.com/role/Cover" xlink:href="ocgn-20210207.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://deitaxonomy.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm215707d2_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm215707d2_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  (H# 2(  A$! Q$!_\0
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M+8#C'C6KG6#R"OC<\P$_JM.O5R+$X_!Y7C\/"KA:-&O[.5.BJE3[_/LF\/\
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M3M>N]-CCU?2[C2KNV>WE^&MK-<V2I<R0O&]O LL"X:) Y _,ZY_9U^/6B_\
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M<6UW:^ /!%K=6UQ$\$]K<0>'-(2>"XAE"2PS021O%-#(BRQR(Z,@96 _%?\
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M,:_H>O1>&=-U#7[2T\8^#/#6FZQI5L1H>L:CJ4T&FR?F%_P:@S-XI3_@H?\
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M>_\ !T?I&EZ7K7_!-WXC6%O9V/CK2OC;XNT73_$4$5M#KJZ1#K/PGU^"V_M
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MQ%I^IV%Y?V5G#>6TD_V)^P%^W)X-_P""@GP7UCXY^ OA9\8?A-X;TOXA:_\
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M>,O#\=SX6T?6;WQ)HJW'AWPQJ]Y,^LZ;8K:36XLY]EQ<01O_ $;("&((  '
M 'MGD=<G\OI2^3'TV]P3\S<D# )YYP,#GL!Z##@J@Y YQCJ3Q^)__77G9GF6
M)S;$4\5BE252E@\%@8*C#V<71P&&CA:$I7E)RJ.E'WW]J3OIL>)Q!Q!C^)<=
M0Q^8QPT:^'RO*LGI1PM)T:2P>2X*EE^"<J<JE5O$/#4DZU5SO.I*4E&,7&,7
(4445YYXA_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  (H# 2(  A$! Q$!_\0
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M+8#C'C6KG6#R"OC<\P$_JM.O5R+$X_!Y7C\/"KA:-&O[.5.BJE3[_/LF\/\
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M3M>N]-CCU?2[C2KNV>WE^&MK-<V2I<R0O&]O LL"X:) Y _,ZY_9U^/6B_\
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M<6UW:^ /!%K=6UQ$\$]K<0>'-(2>"XAE"2PS021O%-#(BRQR(Z,@96 _%?\
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M,:_H>O1>&=-U#7[2T\8^#/#6FZQI5L1H>L:CJ4T&FR?F%_P:@S-XI3_@H?\
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M>_\ !T?I&EZ7K7_!-WXC6%O9V/CK2OC;XNT73_$4$5M#KJZ1#K/PGU^"V_M
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MQ%I^IV%Y?V5G#>6TD_V)^P%^W)X-_P""@GP7UCXY^ OA9\8?A-X;TOXA:_\
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M>,O#\=SX6T?6;WQ)HJW'AWPQJ]Y,^LZ;8K:36XLY]EQ<01O_ $;("&((  '
M 'MGD=<G\OI2^3'TV]P3\S<D# )YYP,#GL!Z##@J@Y YQCJ3Q^)__77G9GF6
M)S;$4\5BE252E@\%@8*C#V<71P&&CA:$I7E)RJ.E'WW]J3OIL>)Q!Q!C^)<=
M0Q^8QPT:^'RO*LGI1PM)T:2P>2X*EE^"<J<JE5O$/#4DZU5SO.I*4E&,7&,7
(4445YYXA_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>tm215707d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ocgn-20210207.xsd" xlink:type="simple"/>
    <context id="From2021-02-07to2021-02-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
        </entity>
        <period>
            <startDate>2021-02-07</startDate>
            <endDate>2021-02-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-02-07to2021-02-07">0001372299</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-02-07to2021-02-07">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-02-07to2021-02-07">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-02-07to2021-02-07">2021-02-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-02-07to2021-02-07">OCUGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-02-07to2021-02-07">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-02-07to2021-02-07">001-36751</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-02-07to2021-02-07">04-3522315</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-02-07to2021-02-07">263 Great Valley Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-02-07to2021-02-07">Malvern</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-02-07to2021-02-07">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-02-07to2021-02-07">19355</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-02-07to2021-02-07">484</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-02-07to2021-02-07">328-4701</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-02-07to2021-02-07">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-02-07to2021-02-07">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-02-07to2021-02-07">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-02-07to2021-02-07">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-02-07to2021-02-07">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-02-07to2021-02-07">OCGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-02-07to2021-02-07">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-02-07to2021-02-07">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140293561846024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 07, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  07,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OCUGEN, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3522315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">263 Great Valley Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Malvern<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">328-4701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OCGN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MVGJ_,=T/K$KSS>!"6=A:YH=KV,QS[6Z ZTNE[/O [2^+?P\,_@902P,$%
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ PXI)4JK$(A8S 0  (@(   \
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M4$L! A0#%     @ PXI)4N#-+MOM    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ PXI)4IE<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " ##BDE2P'G/>3($   J$   &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ PXI)4H.II0/4 0  ,@8
M  T              ( != P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " ##
MBDE2EXJ[',     3 @  "P              @ %S#@  7W)E;',O+G)E;'-0
M2P$"% ,4    " ##BDE2JL0B%C,!   B @  #P              @ %<#P
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ PXI)4B0>FZ*M    ^ $  !H
M             ( !O!   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ PXI)4F60>9(9 0  SP,  !,              ( !H1$  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ZQ(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm215707d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://deitaxonomy.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm215707d2_8k.htm">tm215707d2_8k.htm</File>
    <File>ocgn-20210207.xsd</File>
    <File>ocgn-20210207_lab.xml</File>
    <File>ocgn-20210207_pre.xml</File>
    <File>tm215707d2_ex10-1.htm</File>
    <File>tm215707d2_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm215707d2_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm215707d2_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ocgn-20210207_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ocgn-20210207_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ocgn-20210207.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ocgn",
   "nsuri": "http://deitaxonomy.com/20210207",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm215707d2_8k.htm",
      "contextRef": "From2021-02-07to2021-02-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://deitaxonomy.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm215707d2_8k.htm",
      "contextRef": "From2021-02-07to2021-02-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://deitaxonomy.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-21-016781-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-016781-xbrl.zip
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M^,=67ML30?>]:+24KND K)J &+*@&+%[ S&IY"&0LA28I8EJTGI1:4N=7Y(
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MIBH@1 !K ".E&BWF,_]]RQ+OYK&$-GE(BO?0>U@!]6Z1Z;'=) <0!P10MT.
M(QF$FE'^<9JSB(MG7GN=8L:WLDG<SW@,CUQZHMRB-:@(3< Z0P+";(A/ +9&
MZ(?BG1?$U1RB/ .D<O#(W44<R].5EO]<)XQ,P;-@U;IEK,-NDRR+,"">8'<
M1:7R@]Y *@;=LK#0.7E#@4_\HW,R%)V3H-$Y>0\ZRU<>%#JG;RCPJ7]T3H>B
M<QHT.J?O0D=6?P#MSDQNWHHE?[6]&@XJO8#3MFK%YB +#YJ6MSYD5( :YZ@0
M_[#DPZY;<2?X2\(B>$ -R;U@ YBVLF-HPP/(;K"/HFJXK./\HU0.W'O_8+3,
M3XO3-&EO;@I->*@TC?4V-(7:/QAW/,TP_7?RW'G);A=[@<1JV(I*0QD>,#9[
M?=@4,4@&^;L$+]%5#T:L$]R,='=3E2VV#E.5:XE!H&!SU)ZJ7-QM*41^*EOQ
M*@@&6H=FLK.JMIBJ:KJ6%D9%MPVUZCG_&Y<:?W_4:ET:>O?(&?SJ05OBJKXA
M<[K.S?0@ZATP9=9]+D.YSNO]?+5"1FIOT&MISGI\TT[5P>N$(.K8=-/JOG6Z
MESK]3229//Z,;S9;5CXSLKVI".A<U76G35WO5E$0#'0Y,WDHM:@I]@+'@M,D
M2K*$K7^5%ZLBP;:RV42NL( -:B;:BB"  &V9-!R$2"N]H' GB *2R.K(IRFJ
MI9+$[<.#=130)7:%1K]AC0BL# *57GLF,C)@'-4B4!&"\I@0X)FGZ9:(-R%D
M"?$$$F@>P*FE#Q$JR&0O6D6@?\(6)-K*?G,_/5DMDXS:+D/;$F>]%&"NZJ.,
M]" ( 4R91.1IB#^@Z<E?5W]#.LH+!#=\*;!:'G>QWZPX!=;3LJI<H=!A4=-@
MD00!!.S+9.*&HU**"JV_];8:EBV%,M)=86"UI0%H) 91]39'K8:@4>->.X'+
M7?0HK1%@:H1=YKHSL)DT.X2Z)@@0.HRU+EQ**=):?U,C#EW9NG]PL/8V.%CW
M# [6(0X.UD,'!VO/@P-]\&*A$]E2W:YHLL;  HR=:M=H=%@V*;%(@P(&]@>V
M'U4(.L3X6;LS7\!-?:! ;'(75W+#4E9 YVSUSBZ;U?*=-E$0I'0Y:RW@62RI
M5Q,CI?9#QS9.,A(7EJX2AEF48%HM!&F[I]X?XHR9@>8K?'KT89 TS&0+JB),
MK]=8!1X6]?1S,[YXS>,W0NDOC+^R!<$I9R0N[L#8GCMUZ]V^E]-CN_EJ#B .
M JHA#H$7=%30^$E%(1U6WC_SR-,W3K<LPR*?_RYLK12@<\L/8+/)C2$*B!>[
M,X"32HP*M<_IY,7J%]40K/@B$UA,2.YX<GFG:6..N54;$#F=!J$9Y^6:)8>1
M<Q'E=1)H1M27-)(7\@5GN'0(EAJ2NY[VV67:G.]ITP8$4J=!<(9G%:,6O,&:
M+,\+WXB9'(BM><>;ZH;*_?(W+8OM%7 J24"0V'QUK(,CD-9Z)&*QP91^WJ8)
M(RG<-1DJMT18+3:):$@"(L+F"R BER*M]4C$Y8:(M>SV?A;\-7LL5Z4%2PBH
MW1+2:;E)BE4:$#%=_@!R= @J8O1"PCX1VAT65B_6DX3+:Y$ZA@<T:Y#3TH6$
M#62NQ0PED;H_<\,SM.3H:TI0]DC09?GYOOJ*^$4^?K_!$D5J@D8Q<F<Q%C:0
MNL3.O\<"&FY]E:6E# *G7GOP%UJJ"*1#O+!S*WD6]2N^W,H\(QMPWD5_B"N.
MAIK7-/7I@V!JH$F3K#RL>1F>!R(5Z7]EIOI2__  L"%R/&ZV&#2&S35%$*2
MMJ!!<_W+"3Y7!MRN:!)=48[ANS(-C>/U -OVC*4 #X* .&B[@A8 S(4H5WJD
MX#-F3V+[G$7[.\$C0M0;76G5?O7=M1L8[9:<-Q6IR=2@T(!H>XM?@,-#%JB6
MQX=:'^;_%J!Z<5VM5<>CI\4CEJ?Q=INEJF>5]N#[Z)U!CA]0#"B \9BB(R(@
M  ?8A!Y9Y)$H#_V BF!4B_9Z#9<>5CHD\>?]/7D@0LV 6))=]ED>[JGC*F1
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M#(7SHZ(NZM3>K.<KS=SV"?4PF?A&Y) ]E#M*GE@M]!SX#[3.J#HU"B6EH+%
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M7TNGE=)Y!B!4MJ29F2$#7C9OO"5/2#NP,&9'$"C%["W$2=+U5, 6]K(5104
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M@MZ"">MT*%[;Y5%>4MT1@IM*H7KD3W'TL0=C(WL&,%]0!;$8>1(:@JKA@8,
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MJ!' 1?D&"[A2,1 F<X0J"L7SD[9J\RQ;J2K%IXB9&__6]FBQ((#@Q-D46A8
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M7DU"%-('6G&0-"ZC#BL2IQ@6F> Z]^&R9H0/POAH-+%KO4T([%I0TPRL8CN
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MPHC]O:Y>P24G*Q?SOS>K.]AG/R7?X6<S.H?NLU_AD+]+CF%L;5T6.8QO,(G
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M^X =4H3!4BP.+-ODO[X_^NZ1+H%-LAP?0[;A@E"JO 92C7B-$&P=&TKEK[Q
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M@ML2$NG5(_U!HG-_GJ2VIN:RI8+3":Z^_IC";4,L6]0;%!$E&,="ML)6_^K
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M*FIQ*_ 2D/G9NNRLJ).IHI[4K4T/1C0><WPM6G=#8A@)*N8EB[Q@/E-0#+P
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M G5LP.GH3+A#6"D.SD#B9%=*O5VOBGQ-.I*U!XXCN[C )J'@MR% 9:,4&ZL
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M =UN.<XMY#CV1AD2ORL\U2!?3C!>HL>!;T[NWS]ATXRL3=?<(F1_3FQEE*/
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M7]L.G SQ8+GI:\<MT)5Y'EK.1)&< UT0Q4)<?5#8B9/Z1=/U)&L=N>A0E$7
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M2*YW:H=FH\#2XX#ESZ9N9]-)0-L?Y'+C *:"0VYL>.;FP3?^LK4)WC[TC</
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MSX@BOO66IW\WY(3:> \Z<Y?RD845$H2>'2/P^ HF4J_PW.1U'T&!)WRD1"E
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MHA&G25'WPMGZX']*NPHRGT2!M(Z-PC@.9TCDR6BK46V^[%1;S=?;K(FJ:,)
M^FMP^YJFCR(U,VG'UO.57F&KCT35HNK=J+<Z4CEIC]M B@UCM:'\PZY5@R/V
MJ4NF'S.0&DL=!A'^55<N-]E/B8GE>.YZSVI7:75^7\;UP8J7U'>*\@(QCK."
MO%B]YL1<YS8=<B9&&L5QSO:JK-5H-=/@L(Y<[\;'\MCC<I8<SJ.0:Y^%8W8B
MM?#B4)M-GWCE)1.AJLZ\<^75-WU@ZU6;O=."Q^P##P(Q9WVN;^[X?-/G7O
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MR3OI[XS2._!Z,]O(1^&MJ/G">%J.:$Y;"AH[\83I%5$:)ZD/Z/Y8ZAE+\AM
MCT?6N>E UK-7<1?NGB&=QC+?+J+(W@Q.Y*VT\Y\TF6%VGO5#>X44IS9S'[.O
MG6C+I73:Y?EQXCY"[<O.H:1+SYH)KG)LEJ;5KF>OAII[[?;2#<:S#Z+*VP\4
M^[%.,'[1C;VI/F=E=\P.&UY?_3F\Z%ZR_FF_?WK-WG<OSGO#JTLVZ%Z>G%X/
MW*^LGJL-7\C:G]NH[YMM6P?LRN:UV2>Y@[2K];@!N_M ]PM8\S3S[U?)I8>B
M(?3*[TG6G&D)4*UH<6;K 1O.(\CN:CZ2W@&[1#UP>%R&9&!K:=+-=M$WM:>;
MB3<<V@[%0F3LT ]JW2]LZ8>X_P-02P$"% ,4    " ##BDE2$TG8XT$#  "9
M#   $0              @ $     ;V-G;BTR,#(Q,#(P-RYX<V102P$"% ,4
M    " ##BDE2E58)K/X*  #@AP  %0              @ %P P  ;V-G;BTR
M,#(Q,#(P-U]L86(N>&UL4$L! A0#%     @ PXI)4O1%+#%9!P  .UD  !4
M             ( !H0X  &]C9VXM,C R,3 R,#=?<')E+GAM;%!+ 0(4 Q0
M   ( ,.*25+WL42Y;BL  -S1   1              "  2T6  !T;3(Q-3<P
M-V0R7SAK+FAT;5!+ 0(4 Q0    ( ,.*25(D?*5KEXD  'L  P 5
M      "  <I!  !T;3(Q-3<P-V0R7V5X,3 M,2YH=&U02P$"% ,4    " ##
MBDE2H3XOMSL*  "/*P  %               @ &4RP  =&TR,34W,#=D,E]E
>>#4M,2YH=&U02P4&      8 !@") 0   =8

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
